Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Objective: Psilocybin is a serotonin receptor agonist with a therapeutic potential for treatment-resistant depression and other psychiatric illnesses. We investigated whether the administration of psilocybin had an antidepressant-like effect in a rat model of depression. Methods: Using the Flinders Sensitive Line (FSL) rat model of depression, we assessed the antidepressant-like effect of psilocin and psilocybin, measured as a reduction in immobility time in the forced swim test (FST). We measured locomotor activity in an open field test (OFT) to control for stimulant properties of the drugs. We performed a set of experiments to test different doses, treatment paradigms, and timing of the tests in relation to the drug administration. Results: Psilocin and psilocybin showed no effect on immobility, struggling, or swimming behaviour in the FST and no effect on locomotor activity in the OFT. FSL rats did show significantly more immobility than their control strain, the Flinders Resistant Line, as expected. Conclusion: Psilocin and psilocybin showed no antidepressant-like effect in the FSL rats, despite a positive effect in humans. This suggests that other animal models of depression and other behavioural tests may be more appropriate for translational studies in the effects of psilocybin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Current treatment options, such as antidepressant medication and cognitive behavioural therapy, can be effective for some patients; however, around 20% do not respond to any intervention, the time to response is often several weeks, and many of those that do respond relapse (Rush et al., 2006).”
BackgroundFerrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“…serotonin receptor agonist found in ‘magic mushrooms’, has shown a promising therapeutic potential for treatment-resistant depression (Carhart-Harris et al., 2016), end-oflife anxiety (Griffiths et al., 2016; Ross et al., 2016), and addiction (Johnson et al., 2014; Bogenschutz et al., 2015).”
BackgroundMethodInfluentialCost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“…a psychedelic serotonin receptor agonist found in ‘magic mushrooms’, has shown a promising therapeutic potential for treatment-resistant depression (Carhart-Harris et al., 2016), end-oflife anxiety (Griffiths et al., 2016; Ross et al., 2016), and addiction (Johnson et al., 2014; Bogenschutz et…”
BackgroundSelf-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“…serotonin receptor agonist found in ‘magic mushrooms’, has shown a promising therapeutic potential for treatment-resistant depression (Carhart-Harris et al., 2016), end-oflife anxiety (Griffiths et al., 2016; Ross et al., 2016), and addiction (Johnson et al., 2014; Bogenschutz et al., 2015).”
BackgroundPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 2×
“…render this strain inappropriate for studying psilocybin and psilocin, since the activation of the 5-HT2A receptor has been shown to be necessary for their subjective effects in humans (Vollenweider et al., 1998; Quednow et al., 2012) and behavioral effects in rodents (Gonzalez-Maeso et al., 2007).”
BackgroundGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 1×
“…render this strain inappropriate for studying psilocybin and psilocin, since the activation of the 5-HT2A receptor has been shown to be necessary for their subjective effects in humans (Vollenweider et al., 1998; Quednow et al., 2012) and behavioral effects in rodents (Gonzalez-Maeso et al., 2007).”
BackgroundPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 1×
“…serotonin receptor agonist found in ‘magic mushrooms’, has shown a promising therapeutic potential for treatment-resistant depression (Carhart-Harris et al., 2016), end-oflife anxiety (Griffiths et al., 2016; Ross et al., 2016), and addiction (Johnson et al., 2014; Bogenschutz et al., 2015).”
BackgroundUsing the rat forced swim test to assess antidepressant-like activity in rodents
Slattery, D. A., & Cryan, J. F. (2012) · Nature Protocols · doi:10.1038/nprot.2012.044 · Cited by 903 · cited 2×
“6, based on the assumption that a putative antidepressant effect should reduce immobility in the FST by at least 20% to be considered significant (Slattery and Cryan, 2012), and a standard deviation (SD) of 12.”
BackgroundMethodInfluentialDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · cited 1×
“One way to do this is by re-evaluating and repurposing old drugs, as has been the case of ketamine (Canuso et al., 2018; Daly et al., 2018).”
BackgroundCanuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior
Commons, K. G., Cholanians, A. B., Babb, J. A., & Ehlinger, D. G. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00042 · Cited by 525 · cited 1×
“Furthermore, interpreting any single behaviour as depressive-like may be too anthropomorphic or simplistic (Slattery and Cryan, 2014; Commons et al., 2017).”
BackgroundKetamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339 · cited 1×
“This is in contrast to the rapid antidepressant effect of ketamine, which typically only lasts up to a week (Fond et al., 2014).”
ResultVollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305 · cited 2×
“35 mg/kg) have also been found to increase dopamine levels in ventral striatum (NAc and olfactory tuberculum) in human PET studies (Vollenweider et al., 1999).”
BackgroundInfluentialPhenomenology, Structure, and Dynamic of Psychedelic States
Preller, K. H., & Vollenweider, F. X. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_459 · Cited by 282 · cited 1×
“Psilocybin acutely induces powerful subjective effects, produces visual hallucinations, enhances positive mood, alters states of consciousness (Preller and Vollenweider, 2018), and has been used as a model of psychosis both in humans (Vollenweider et al.”
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 1×
“Other studies have investigated the therapeutic potential of psilocin or psilocybin in animal models of other psychiatric disorders such as anxiety (Horsley et al., 2018), OCD (Sard et al., 2005), and PTSD (Catlow et al., 2013).”
BackgroundEffects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171
Sakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., Horiguchi, Y., & Taguchi, K. (2015) · Biological ^|^ Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00315 · Cited by 81
Cited by
Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022489118 · Cited by 378
“Although psilocybin has been reported to have delayed antidepressant-like effects in the forced swim test in some, but not all, strains of rats (13, 33), we were unable to replicate this finding in mice.”
BackgroundHibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00493 · Cited by 205
Jefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127
Self-citationMeinhardt, M. W., Pfarr, S., Fouquet, G., Rohleder, C., Meinhardt, M. L., Barroso-Flores, J., Hoffmann, R., Jeanblanc, J., Paul, E., Wagner, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2399 · Cited by 89
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“The aforementioned study did not find significant changes in the sucrose preference test or the FST following psilocybin in C57BL/6J male mice (130), echoing a previous study which did not show effects of psilocin or psilocybin on the FST or in the OFT in Flinders Sensitive Line rats (131).”
Result
Metadata
- Authors
- Jefsen, O., Højgaard, K., Christiansen, S. L., Elfving, B., Nutt, D. J., Wegener, G., & Müller, H. K.
- Venue
- Acta Neuropsychiatrica
- Publisher
- Cambridge University Press (CUP)
- Published
- 2019-05-20
- Volume
- 31
- Issue
- 04
- Pages
- 213-219
- ISSN
- 0924-2708 (ISSN-L)
- 1601-5215
- OpenAlex
- W2945318261
- Cited by
- 63
- References
- 21
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.